Developing preclinical models of neuroblastoma: driving therapeutic testing
KJ Ornell, JM Coburn - BMC biomedical engineering, 2019 - Springer
Despite advances in cancer therapeutics, particularly in the area of immuno-oncology,
successful treatment of neuroblastoma (NB) remains a challenge. NB is the most common …
successful treatment of neuroblastoma (NB) remains a challenge. NB is the most common …
Ponatinib inhibits proliferation and induces apoptosis of liver cancer cells, but its efficacy is compromised by its activation on PDK1/Akt/mTOR signaling
C Liu, X Mu, X Wang, C Zhang, L Zhang, B Yu, G Sun - Molecules, 2019 - mdpi.com
Ponatinib is a multi-target protein tyrosine kinase inhibitor, and its effects on hepatocellular
carcinoma cells have not been previously explored. In the present study, we investigated its …
carcinoma cells have not been previously explored. In the present study, we investigated its …